Home Latest News Jan Keltjens is the new president and CEO of Endosense

Jan Keltjens is the new president and CEO of Endosense

Jan Keltjens is the new president and CEO of Endosense

Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has appointed Jan Keltjens as president and chief executive officer.

Keltjens brings to Endosense more than two decades of leadership experience in the medical device and technology sectors. He has previously served as chief executive officer of AngioDynamics and CryoCath Technologies (now Medtronic CryoCath) and held a number of senior leadership positions at Cordis.

Keltjens replaces outgoing president and CEO Eric Le Royer who is retiring from Endosense after leading the firm from its first venture capital financing seven years ago. Under Keltjens leadership, the company will relentlessly focus on the global commercialisation of its proprietary TactiCath, the world’s first contact-force sensing ablation catheter. As part of this effort, Endosense is rapidly enrolling patients in its TOCCASTAR investigational device exemption (IDE) clinical trial, the results of which will be used to support a premarket approval filing to the US FDA for market clearance of the TactiCath in the United States.

“Endosense is creating a breakthrough in the field of catheter ablation with its TactiCath contact-force sensing catheter, which gives physicians critical therapeutic information to improve procedure safety and effectiveness. We believe this new technology will have a profound, positive impact on clinical practice, benefitting both patients and physicians, and we are delighted that Jan has agreed to join Endosense to help the company deliver on this promise,” said Jan Egberts, chairman of the Endosense board of directors. “We would also like to thank Eric for all he has done for Endosense. Through his energy, focus and dedication, he and his team have transformed contact-force sensing from an early vision into a clinical reality and have positioned Endosense to become a leader in the rapidly growing atrial fibrillation market.”